Pembrolizumab monotherapy for advanced chordoma

Lancet Oncol. 2023 Oct;24(10):e399. doi: 10.1016/S1470-2045(23)00395-9.

Authors

Xianglin Hu¹, Chunmeng Wang¹, Wending Huang¹, Sean M Barber², Wangjun Yan³

Affiliations

¹ Department of Musculoskeletal Oncology, Spine Tumor Center, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
² Department of Neurosurgery, Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, TX, USA.
³ Department of Musculoskeletal Oncology, Spine Tumor Center, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China. Electronic address: yanwj@fudan.edu.cn.

PMID: 37797637
DOI: 10.1016/S1470-2045(23)00395-9

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung* / drug therapy
Chordoma* / drug therapy
Humans
Lung Neoplasms* / drug therapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
B7-H1 Antigen